MapLight Therapeutics reports RSU settlement of 7,305 shares
MapLight Therapeutics reported the settlement of 7,305 restricted stock units into MapLight voting common stock on 04/15/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics reported the settlement of 7,305 restricted stock units into MapLight voting common stock on 04/15/2026. The filing states the units were a vested grant settled in stock and the consideration was the reporting person’s continued service as an employee.
Insights
Notice documents a routine RSU settlement by an insider.
The filing records a vested restricted stock unit settlement of 7,305 shares into voting common stock on 04/15/2026. It identifies the consideration as the reporting person’s continued service, indicating a compensation-related conversion rather than an open-market sale.
Cash‑flow treatment and any subsequent sale plans are not stated in the excerpt; subsequent filings would show any intended disposition.
Key Figures
Key Terms
Restricted stock unit financial
Vested grant financial
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MapLight Therapeutics (MPLT) report in this Form 144?
Was the RSU settlement described as a sale or market transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.